Skip to main content
Premium Trial:

Request an Annual Quote

Natera Receives Medicare Coverage for Prospera Lung Transplant Rejection Test

NEW YORK – Natera announced Wednesday that its Prospera Lung allograft rejection monitoring platform met MolDx coverage requirements and will receive Medicare coverage.

The donor-derived cell-free DNA (dd-cfDNA)-based test will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection for use in the surveillance setting in lung transplant patients.

The Austin, Texas-based company had generated positive data for Prospera's clinical utility in monitoring heart, lung, and kidney transplants through three studies published last year. Natera noted in November in its third quarter 2022 earnings call that while Prospera volumes were growing, the tests were not yet contributing significantly to revenue, pending reimbursement decisions.

"Medicare's decision enables broad access to the Prospera Lung test and represents a significant win for lung transplant patients and the field of transplant monitoring," Bernie Tobin, general manager of organ health at Natera, said in a statement. 

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.